Alector, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Alector, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.05M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $100.56M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $97.10M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $133.60M | Feb 26, 2025 |
| FY2020 | Dec 31, 2020 | $21.10M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $6.00M | Mar 24, 2020 |
| FY2019 | Sep 30, 2019 | $2.70M | Mar 24, 2020 |
| FY2019 | Jun 30, 2019 | $6.92M | Mar 24, 2020 |
| FY2019 | Mar 31, 2019 | $5.61M | Mar 24, 2020 |
| FY2019 | Dec 31, 2018 | $9.15M | Mar 24, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.05M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $100.56M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $97.06M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $133.62M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $207.09M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $21.10M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $21.22M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $27.51M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $2.87M | Mar 24, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($142.93M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($119.05M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($130.39M) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | ($133.31M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($36.33M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($190.23M) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | ($30.53M) | Mar 24, 2020 |
| FY2019 | Sep 30, 2019 | ($31.74M) | Mar 24, 2020 |
| FY2019 | Jun 30, 2019 | ($24.56M) | Mar 24, 2020 |
| FY2019 | Mar 31, 2019 | ($18.56M) | Mar 24, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($156.01M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($145.00M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($151.74M) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | ($137.83M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($37.36M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($195.17M) | Feb 28, 2023 |
| FY2019 | Dec 31, 2019 | ($32.34M) | Mar 24, 2020 |
| FY2019 | Sep 30, 2019 | ($34.15M) | Mar 24, 2020 |
| FY2019 | Jun 30, 2019 | ($27.15M) | Mar 24, 2020 |
| FY2019 | Mar 31, 2019 | ($20.76M) | Mar 24, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.07M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $185.94M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $192.12M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $210.42M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $189.41M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $156.87M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $100.53M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $73.03M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $29.91M | Mar 24, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($184.03M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($229.91M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($184.16M) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | ($20.33M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $298.55M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($166.73M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($99.31M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $127.46M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($17.77M) | Mar 24, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.26M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $2.38M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $4.12M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $3.25M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $5.03M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $15.27M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.88M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $801.0K | Mar 24, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $293.24M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $468.30M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $621.83M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $787.65M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $814.66M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $488.25M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $421.91M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $308.36M | Mar 24, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $262.59M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $341.50M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $487.67M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $573.21M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $513.93M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $220.72M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $227.17M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $195.24M | Mar 24, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.65M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $126.80M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $134.16M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $214.44M | Feb 26, 2025 |
| FY2024 | Dec 31, 2021 | $300.72M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $267.53M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $194.74M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | ($97.40M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | ($52.03M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | ($24.91M) | Mar 24, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($972.06M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($829.13M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($710.08M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($579.69M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($446.38M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($410.05M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($219.82M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($114.44M) | Mar 24, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.80M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $33.02M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $74.56M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $154.32M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $329.15M | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $49.97M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $89.64M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $65.47M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $32.45M | Mar 24, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2024 | $10.00M | Feb 26, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 110.36M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 99.09M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 84.88M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 82.90M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 81.99M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 79.32M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 69.05M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 13.76M | Mar 24, 2020 |